1
|
Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2023; 24:1181-1195. [PMID: 37875143 DOI: 10.1016/s1470-2045(23)00515-6] [Citation(s) in RCA: 24] [Impact Index Per Article: 24.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2023] [Revised: 09/26/2023] [Accepted: 09/27/2023] [Indexed: 10/26/2023]
Abstract
BACKGROUND PD-1 inhibitors combined with chemotherapy have shown efficacy in gastric or gastro-esophageal junction cancer. We compared the efficacy and safety of pembrolizumab plus chemotherapy with placebo plus chemotherapy in participants with locally advanced or metastatic HER2-negative gastric or gastro-esophageal junction adenocarcinoma. METHODS KEYNOTE-859 is a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial, done at 207 medical centres across 33 countries. Eligible participants were aged 18 years and older with previously untreated histologically or cytologically confirmed locally advanced or metastatic HER2-negative gastric or gastro-esophageal junction adenocarcinoma and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned (1:1) to receive pembrolizumab or placebo 200 mg, administered intravenously every 3 weeks for up to 35 cycles. All participants received investigator's choice of fluorouracil (intravenous, 800 mg/m2 per day) administered continuously on days 1-5 of each 3-week cycle plus cisplatin (intravenous, 80 mg/m2) administered on day 1 of each 3-week cycle or capecitabine (oral, 1000 mg/m2) administered twice daily on days 1-14 of each 3-week cycle plus oxaliplatin (intravenous, 130 mg/m2) administered on day 1 of each 3-week cycle. Randomisation was done using a central interactive voice-response system and stratified by geographical region, PD-L1 status, and chemotherapy in permuted block sizes of four. The primary endpoint was overall survival, assessed in the intention-to-treat (ITT) population, and the populations with a PD-L1 combined positive score (CPS) of 1 or higher, and PD-L1 CPS of 10 or higher. Safety was assessed in the as-treated population, which included all randomly assigned participants who received at least one dose of study intervention. Here, we report the results of the interim analysis. This study is registered with ClinicalTrials.gov, NCT03675737, and recruitment is complete. FINDINGS Between Nov 8, 2018, and June 11, 2021, 1579 (66%) of 2409 screened participants were randomly assigned to receive pembrolizumab plus chemotherapy (pembrolizumab group; n=790) or placebo plus chemotherapy (placebo group; n=789). Most participants were male (527 [67%] of 790 participants in the pembrolizumab plus chemotherapy group; 544 [69%] of 789 participants in the placebo plus chemotherapy group) and White (426 [54%]; 435 [55%]). Median follow-up at the data cutoff was 31·0 months (IQR 23·0-38·3). Median overall survival was longer in the pembrolizumab group than in the placebo group in the ITT population (12·9 months [95% CI 11·9-14·0] vs 11·5 months [10·6-12·1]; hazard ratio [HR] 0·78 [95% CI 0·70-0·87]; p<0·0001), in participants with a PD-L1 CPS of 1 or higher (13·0 months [11·6-14·2] vs 11·4 months [10·5-12·0]; 0·74 [0·65-0·84]; p<0·0001), and in participants with a PD-L1 CPS of 10 or higher (15·7 months [13·8-19·3] vs 11·8 months [10·3-12·7]; 0·65 [0·53-0·79]; p<0·0001). The most common grade 3-5 adverse events of any cause were anaemia (95 [12%] of 785 participants in the pembrolizumab group vs 76 [10%] of 787 participants in the placebo group) and decreased neutrophil count (77 [10%] vs 64 [8%]). Serious treatment-related adverse events occurred in 184 (23%) participants in the pembrolizumab group and 146 (19%) participants in the placebo group. Treatment-related deaths occurred in eight (1%) participants in the pembrolizumab group and 16 (2%) participants in the placebo group. No new safety signals were identified. INTERPRETATION Participants in the pembrolizumab plus chemotherapy group had a significant and clinically meaningful improvement in overall survival with manageable toxicity compared with participants in the placebo plus chemotherapy group. Therefore, pembrolizumab with chemotherapy might be a first-line treatment option for patients with locally advanced or metastatic HER2-negative gastric or gastro-esophageal junction adenocarcinoma. FUNDING Merck Sharp and Dohme.
Collapse
Affiliation(s)
- Sun Young Rha
- Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
| | - Do-Youn Oh
- Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea
| | - Patricio Yañez
- Department of Internal Medicine, James Lind Cancer Research Center, Universidad de La Frontera, Temuco, Chile
| | - Yuxian Bai
- Department of Gastrointestinal Oncology, Harbin Medical University Cancer Hospital, Harbin, China
| | - Min-Hee Ryu
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
| | - Jeeyun Lee
- Department of Medicine, Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea
| | - Fernando Rivera
- Department of Medical Oncology, University Hospital Marqués de Valdecilla, IDIVAL, Santander, Spain
| | - Gustavo Vasconcelos Alves
- Centro Integrado de Pesquisa em Oncologia, Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil
| | - Marcelo Garrido
- Department of Hemato-Oncology, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Kai-Keen Shiu
- Gastrointestinal Oncology Service, University College London Hospitals, University College London Cancer Institute, NHS Foundation Trust, London, UK
| | | | - Jin Li
- Department of Medical Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China
| | - Maeve A Lowery
- Department of Medical Oncology, Trinity St James Cancer Institute, Dublin, Ireland
| | - Timuçin Çil
- Department of Medical Oncology, Health and Science University, Adana City Hospital, Adana, Turkey
| | - Felipe Melo Cruz
- Department of Medical Oncology, Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil
| | - Shukui Qin
- Department of Medical Oncology, Cancer Center of People's Liberation Army, Nanjing, China
| | - Suxia Luo
- Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China
| | - Hongming Pan
- Department of Medical Oncology, Zhejiang University School of Medicine, Sir Run Run Shaw Hospital, Hangzhou, China
| | - Zev A Wainberg
- David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
| | - Lina Yin
- Biostatistics and Research Decision Sciences, Merck, Rahway, NJ, USA
| | - Sonal Bordia
- Global Clinical Development, Merck, Rahway, NJ, USA
| | - Pooja Bhagia
- Global Clinical Development, Merck, Rahway, NJ, USA
| | - Lucjan S Wyrwicz
- Department of Oncology and Radiotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
| |
Collapse
|
2
|
Cartes C, Segovia C, Salinas-Toro D, Goya C, Alonso MJ, Lopez-Solis R, Zapata C, Cabezas M, Yañez P, Flores-Rodriguez P, Lopez D, Matus G, Traipe L. Dry Eye and Visual Display Terminal-Related Symptoms among University Students during the Coronavirus Disease Pandemic. Ophthalmic Epidemiol 2021; 29:245-251. [PMID: 34251964 DOI: 10.1080/09286586.2021.1943457] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
Purpose: To evaluate dry eye (DE) and subjective visual display terminal (VDT)-related symptoms in university students who moved their classes online due to the COVID-19 pandemic.Methods: Cross-sectional study of students who were taking online classes. In May 2020, the participants completed a Dry Eye Questionnaire (DEQ-5) and a self-report survey, which included demographics, medical history, information on the use of VDT and presence of VDT-related symptoms. Participants were classified as having mild/moderate (7-12) or severe (>12) DE symptoms based on their DEQ-5 score. The associations between severe DE symptoms and relevant factors were also evaluated.Results: The data of 1450 eligible students were analyzed. The mean age of the participants was 21.1 (2.7) years. 42.8% of the participants had mild/moderate DE symptoms, whereas 34.7% had severe symptoms. Associated factors for severe DE were female sex (OR = 2.57, CI [1.97-3.35]), allergic disease (OR = 1.63, CI [1.24-2.13]), previous dry eye diagnosis (OR = 13.49, CI [7.10-25.63]), keratoconus (OR = 5.56, CI [1.27-24.44], contact lens use (OR = 1.77, CI [1.24-2.53]) and duration of VDT use (OR = 1.02, CI [1.01-1.05]). Prior to the pandemic, the mean reported duration of VDT use was 9.8 (4.7) hours; this increased to 15.9 (5.8) hours during the online classes (p < .001). 80.6% of the participants reported a global increase in VDT-related symptoms.Conclusion: Students taking online classes had a high frequency of DE symptoms. They also reported a significant increase in VDT-related symptoms. DE should be considered as an emerging health problem among the young population, which is probably related to the recent changes in lifestyle.
Collapse
Affiliation(s)
- Cristian Cartes
- Unidad de Lágrima y Superficie Ocular (ULSO), Santiago, Chile.,Departamento de Especialidades, Facultad de Medicina, Unidad Oftalmología, Universidad de La Frontera, Temuco, Chile.,Centro de la Visión, Red Centro Oftalmológico Laser, Santiago, Chile
| | | | - Daniela Salinas-Toro
- Unidad de Lágrima y Superficie Ocular (ULSO), Santiago, Chile.,Clínica Las Condes Santiago, Santiago, Chile
| | - Claudia Goya
- Unidad de Lágrima y Superficie Ocular (ULSO), Santiago, Chile
| | | | | | - Claudia Zapata
- Unidad de Lágrima y Superficie Ocular (ULSO), Santiago, Chile.,Centro de la Visión, Red Centro Oftalmológico Laser, Santiago, Chile
| | - Mauricio Cabezas
- Unidad de Lágrima y Superficie Ocular (ULSO), Santiago, Chile.,Clínica Las Condes Santiago, Santiago, Chile
| | - Patricio Yañez
- Unidad de Lágrima y Superficie Ocular (ULSO), Santiago, Chile
| | | | - Daniela Lopez
- Unidad de Lágrima y Superficie Ocular (ULSO), Santiago, Chile.,Clínica Las Condes Santiago, Santiago, Chile
| | - Gonzalo Matus
- Unidad de Lágrima y Superficie Ocular (ULSO), Santiago, Chile.,Clínica Las Condes Santiago, Santiago, Chile
| | - Leonidas Traipe
- Unidad de Lágrima y Superficie Ocular (ULSO), Santiago, Chile.,Clínica Las Condes Santiago, Santiago, Chile
| |
Collapse
|
3
|
Salinas-Toro D, Cartes C, Segovia C, Alonso MJ, Soberon B, Sepulveda M, Zapata C, Yañez P, Traipe L, Goya C, Flores P, Lopez D, Lopez R. High frequency of digital eye strain and dry eye disease in teleworkers during the coronavirus disease (2019) pandemic. Int J Occup Saf Ergon 2021; 28:1787-1792. [PMID: 34082647 DOI: 10.1080/10803548.2021.1936912] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Objectives. This study aimed to evaluate visual display terminal (VDT)-related digital eye strain (ES) and dry eye disease (DED) symptoms in subjects whose work was changed to teleworking (TW) during the coronavirus pandemic. Methods. A digital self-reported survey was conducted on subjects in TW, including demographics, medical history, VDT time and ES-related symptoms before and during the pandemic and DED (dry eye questionnaire 5 [DEQ-5] questionnaire). Results. A total of 1797 questionnaires were analyzed. Mean age was 40.5 (SD 11.1) years, and 69.9% were female. The mean number of TW weeks was 10.2 (SD 3.0). The total VDT total hours increased from 7.4 (SD 3.3) to 9.5 (SD 3.3) (p < 0.001). All ES symptoms presented a significant increase (p < 0.001). The mean DEQ-5 score was 8.3 (SD 4.9). The oldest group presented lower values, and women had a higher score (p < 0.001). Additionally, 28.6% of the subjects were classified with severe DED, and the variables associated with a logistic regression model were total VDT hours, female gender, refractive surgery, rosacea, depression, previous DED, keratoconus and blepharitis. Conclusions. The number of VDT hours seemed to be a relevant factor for increase in ES symptoms and a high prevalence of DED during the pandemic period.
Collapse
Affiliation(s)
- Daniela Salinas-Toro
- Unidad de Lágrima y Superficie Ocular (ULSO), Chile.,Ophthalmology Department, Clínica las Condes Santiago, Chile
| | - Cristian Cartes
- Unidad de Lágrima y Superficie Ocular (ULSO), Chile.,Ophthalmology Department, Centro de la Visión, Red Centro Oftalmológico Laser, Chile.,Departamento de especialidades medicas, Facultad de Medicina, Universidad de la Frontera, Chile
| | | | | | | | | | - Claudia Zapata
- Unidad de Lágrima y Superficie Ocular (ULSO), Chile.,Ophthalmology Department, Centro de la Visión, Red Centro Oftalmológico Laser, Chile
| | | | - Leonidas Traipe
- Unidad de Lágrima y Superficie Ocular (ULSO), Chile.,Ophthalmology Department, Clínica las Condes Santiago, Chile
| | - Claudia Goya
- Unidad de Lágrima y Superficie Ocular (ULSO), Chile
| | | | - Daniela Lopez
- Unidad de Lágrima y Superficie Ocular (ULSO), Chile.,Ophthalmology Department, Clínica las Condes Santiago, Chile
| | | |
Collapse
|
4
|
Gaitán MI, Yañez P, Paday Formenti ME, Calandri I, Figueiredo E, Sati P, Correale J. SWAN-Venule: An Optimized MRI Technique to Detect the Central Vein Sign in MS Plaques. AJNR Am J Neuroradiol 2020; 41:456-460. [PMID: 32054616 DOI: 10.3174/ajnr.a6437] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2019] [Accepted: 01/08/2020] [Indexed: 02/02/2023]
Abstract
BACKGROUND AND PURPOSE Multiple sclerosis lesions develop around small veins that are radiologically described as the so-called central vein sign. With 7T MR imaging and magnetic susceptibility-based sequences, the central vein sign has been observed in 80%-100% of MS lesions in patients' brains. However, a lower proportion ∼50% has been reported at 3T using susceptibility-weighted angiography (SWAN). Our aim was to assess a modified version of SWAN optimized at 3T for sensitive detection of the central vein sign. MATERIALS AND METHODS Thirty subjects with MS were scanned on a 3T clinical MR imaging system. 3D T2-weighted FLAIR and optimized 3D SWAN called SWAN-venule, were acquired after injection of a gadolinium-based contrast agent. Patients showing >3 focal white matter lesions were included. The central vein sign was recorded by 2 trained raters on SWAN-venule images in the supratentorial brain. RESULTS Twenty patients showing >3 white matter lesions were included. A total of 380 white matter lesions (135 periventricular, 144 deep white matter, and 101 juxtacortical) seen on both FLAIR and SWAN-venule images were analyzed. Overall, the central vein sign was detected in 86% of the white matter lesions (periventricular, 89%; deep white matter, 95%; and juxtacortical, 78%). CONCLUSIONS The SWAN-venule technique is an optimized MR imaging sequence for highly sensitive detection of the central vein sign in MS brain lesions. This work will facilitate the validation and integration of the central vein sign to increase the diagnostic certainty of MS and further prevent misdiagnosis in clinical practice.
Collapse
Affiliation(s)
- M I Gaitán
- From the Department of Neurology (M.I.G., J.C.), Neuroimmunolgy Section
| | - P Yañez
- Departments of Radiology (P.Y., M.E.P.F.)
| | | | - I Calandri
- Neurology (I.C.), FLENI, Buenos Aires, Argentina
| | | | - P Sati
- Translational Neuroradiology Section (P.S.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland
| | - J Correale
- From the Department of Neurology (M.I.G., J.C.), Neuroimmunolgy Section
| |
Collapse
|
5
|
Casarejos E, Alvarez-Pol H, Cortina-Gil D, Durán I, Izquierdo P, Yañez P, Vilán J. The mechanical design of the BARREL section of the detector CALIFA for R 3B-FAIR. EPJ Web of Conferences 2014. [DOI: 10.1051/epjconf/20146611037] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
6
|
Casarejos E, Alvarez-Pol H, Cortina-Gil D, Durán I, Iglesias A, Izquierdo P, Yañez P, Vilán J. Design and construction of the structure of the DEMONSTRATOR of the CALIFA detector for R 3B-FAIR using carbon-fiber composites. EPJ Web of Conferences 2014. [DOI: 10.1051/epjconf/20146611038] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
7
|
Zonana-Nacach A, Yañez P, Jiménez-Balderas FJ, Camargo-Coronel A. Disease activity, damage and survival in Mexican patients with acute severe systemic lupus erythematosus. Lupus 2008; 16:997-1000. [PMID: 18042596 DOI: 10.1177/0961203307083175] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Systemic lupus erythematosus (SLE) is a clinical syndrome of varying severity. Although the survival and prognosis of SLE have steadily improved, there is a group of patients who present an acute fatal outcome despite aggressive therapy. We designed this study to evaluate the factors associated with mortality in patients with acute severe SLE. During 2004-06, 41 Mexican SLE patients that could not be managed in the out-patient clinic and with acute severe major organ system involvement [nephritis, severe thrombocytopenia (platelet count below 20 000 per microL) acute neuropsychiatric pulmonary, gastrointestinal or cardiac disease and generalized vasculitis] were studied. During the first admission, disease activity (SLE Disease Activity Index (SLEDAI), SLE Activity Measured), damage [SLE International Collaborating Clinics (SLICC)], and therapy were assessed. Survival using Kaplan-Meier curves, odd ratios with 95% confidence interval and logistic regression analysis were used to determine risk factors for mortality. Ninety percent were female with a mean age of 29 +/- 19 years and mean disease duration of 21 +/- 9 months. The principal causes of first admission were renal (27%), SNC (22%) and cardiopulmonary (15%). After a mean follow-up of 9.7 +/- 6 months, 16 (39%) patients died. Deceased patients had significantly higher SLEDAI (P = 0.004), and SLICC (P = 0.03) scores. The manifestations associated with mortality were renal disease activity (odds ratio, OR 4.6, confidence interval, CI 95% 1.0-20.6), infections (OR 3.2 CI 95% 2.0-5.3) and thrombocytopenia (OR 4.0, CI 95% 1.0-15.9). The survival at 9.7 months was 72, 62 and 50% in patients with an SLEDAI score of 3-10, 11-20 and > or =21, respectively. The SLEDAI score, the presence of damage and infection were associated with death in patients with acute severe SLE.
Collapse
Affiliation(s)
- A Zonana-Nacach
- Unidad de Investigación Clínica y Epidemiología, Hospital General Regional No 20, Tijuana, Baja California, Mexico.
| | | | | | | |
Collapse
|
8
|
Zonana-Nacach A, Camargo-Coronel A, Yañez P, Sánchez L, Jimenez-Balderas FJ, Fraga A. Infections in outpatients with systemic lupus erythematosus: a prospective study. Lupus 2002; 10:505-10. [PMID: 11480850 DOI: 10.1191/096120301678416088] [Citation(s) in RCA: 94] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The objective of this study was to assess the incidence and risk factors of infections in 200 SLE outpatients. All outpatients with active or inactive SLE without infections in the previous month were included. They were assessed every 3 months. Major infections were those requiring hospitalization and parental antibiotic therapy; minor infections required oral or topical therapy. Sociodemographic, disease activity using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), therapy and laboratory variables were evaluated. After a follow-up of 22+/-7 months, 65 (32%) patients had infections; 35% of those were major. The most common sites for infection were urinary (26%), skin (23%), systemic (12%), and vaginal (9%). At infection onset, 50 of 65 patients (77%) had disease activity, with a mean SLEDAI score of 6.1. The variables significantly associated with infection in the univariate analyses were the presence of disease activity, SLEDAI score, renal activity, prednisone dose, and IV cyclophosphamide. The only variable associated with infection in the multivariate analyses was a SLEDAI score of 4 or higher. Most infections in SLE outpatients were single, minor, non-life threatening, and associated with disease activity independently of sociodemographic and therapeutic factors.
Collapse
Affiliation(s)
- A Zonana-Nacach
- Department of Rheumatology, Hospital de Especialidades Centro Médico Nacional, Siglo XXI Instituto Mexicano del Seguro Social, Mexico City, Mexico.
| | | | | | | | | | | |
Collapse
|
9
|
Yañez P, la Garza AM, Pérez-Pérez G, Cabrera L, Muñoz O, Torres J. Comparison of invasive and noninvasive methods for the diagnosis and evaluation of eradication of Helicobacter pylori infection in children. Arch Med Res 2000; 31:415-21. [PMID: 11068086 DOI: 10.1016/s0188-4409(00)00087-4] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
BACKGROUND Acquisition of Helicobacter pylori infection occurs mainly during childhood. To study the events associated with H. pylori colonization in children it is important to have reliable diagnostic methods. Our objective was to validate invasive and noninvasive tests for diagnosis of H. pylori infection in children before and after antimicrobial treatment. METHODS Before treatment, invasive rapid urease test (RUT) culture and histology, as well as the noninvasive carbon-13 urea breath test (13C-UBT) and serology were validated in 59 children. The gold standard for H. pylori infection was any of three positives of the five tests. After antimicrobial treatment culture, histology, and 13C-UBT were validated in 43 children to determine eradication. The gold standard for eradication was negative in all three tests. RESULTS For primary diagnosis, RUT was the most sensitive and specific test, followed by 13C-UBT, which performed better than serology, culture, and histology. Concordance tests also showed that RUT and 13C-UBT performed better. For determination of eradication, 13C-UBT and histology were better than culture, which showed poor sensitivity. CONCLUSIONS RUT performed better for primary diagnosis. However, as endoscopy might not be indicated in most children, 13C-UBT could be the test of choice for diagnosis of H. pylori infection both before and after eradication treatment.
Collapse
Affiliation(s)
- P Yañez
- Departamento de Gastroenterología, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), México, D.F., Mexico
| | | | | | | | | | | |
Collapse
|
10
|
Gomez Orbaneja J, Valle Jimenez A, Sanchez Yus E, Yañez P. [Abrikosov's granular cell tumor of the gluteal region]. Actas Dermosifiliogr 1965; 56:257-66. [PMID: 4289437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
|